Hepatitis 2019
Event begins in
Hepatitis-2019 Info
We are honoured to invite you to the 7th International Conference on Hepatitis and Liver Diseases (Hepatitis 2019) to be held in London, UK during May 02-03, 2019. The conference highlights the theme “Raising awareness and advancement towards Hepatitis and Liver Diseases”.
The conference invites Hepatologists, Gastroenterologists, Virologists, Microbiologists, immunologist, Pathologists, Oncologists, Researchers, Students, Young researchers and business delegates across the World.
Hepatitis 2019 Conference is to bring top experts together and delegates for an in-depth discussion on Hepatitis and Liver diseases. To create awareness for both rural and urban population about liver disease it should be diagnosed at early stages. The importance of this conference is to update, clinically relevant audience regarding the evidence supporting current clinical practices in hepatitis. The information presented is intended to enhance clinical competence in the diagnosis and treatment of hepatitis and liver disease.
Conference Highlights
- Hepatitis B
- Hepatitis C
- Hepatitis A, D & E
- Hepatitis Vaccination
- Hepatitis Clinical Research Trials
- Non-viral Hepatitis
- Epidemiology of Hepatitis
- Hepatocellular Carcinoma
- Liver Diseases
- Metabolic Liver diseases
- Hepato-Biliary Disease
- Liver diseases
- Liver Transplantation and Surgery
- Gastroenterology
- HCV/HIV Coinfection
- Hepatitis Diagnosis and Treatment
- Biliary Astresia
- Hepatotoxicity
- Hepatic Encephalopathy
- Gene expression in Hepatitis
- Clinical Trials
Why to attend Hepatitis-2019
The main reason about Hepatitis and Liver Diseases meeting is to discuss about various new approaching technologies, future and current developments and Features of analysis determining the Future of Hepatitis and Liver Diseases. Experts from all over world will discuss the pros and cons of all the developments and how the approaching technologies or procedures can change the face of Hepatology, Hepatologists, Gastroenterologist and Hepatitis and Liver Diseases Lecturers. Also, it is a platform, where everyone can share their ideas and interact with global experts to expand their knowledge in the arena of Hepatitis and Liver Diseases and to build new contacts creating collaborative research opportunities in the sector of Hepatology and related disciplines.
Here are the quick insights of the upcoming Hepatitis Conference 2019 at London, UK
- Meet the Hepatologist and Gastroenterologist from 20+ countries around the globe
- Earn up to 21 CME/ CPD credits
- Meet your peers and evaluate your research in front of experts
- World-class platform to exhibit your products and services
- Special Workshop/ Symposiums, B2B and interactive sessions with industry Sponsors and Exhibitors
- More than 25 presentations from Industry and Academia leaders
- One- on -one interaction, B2B, and B2A etc.
- Well organizing program with 5+ hours of networking sessions
- Interactive panel discussions and Q&A sessions
- Lively Exhibition area filled with the leading industry solution providers
Scientific Sessions
Track 1: Hepatitis B
But there is no such cure for the person those who already in the condition. If you are infected then you can only prevent by taking certain precautions for the spreading the virus to the others.
Hepatitis Conferences| Gastro Conferences| Hepatology Conferences| CME Liver Diseases Events | Hepatitis B Meeting |
Hepatitis is an inflammatory condition of the liver caused by the hepatitis virus. The most observed types of this disease are hepatitis A, hepatitis B and hepatitis C. Globally, 350 million people are chronically infected with any one form of hepatitis and around 500,000 people die every year according to World Health Organization.
Hepatitis A is a simpler form of which does not lead to chronic infections. Patients suffering from hepatitis A recover within two months as this form is less complicated and can be prevented with vaccination.
Although hepatitis B can be prevented by vaccination, once infected, a person can develop lifelong chronic infection resulting into severe liver damage. More than 2 billion people of the global population are infected with hepatitis B. Hepatitis B patients are vulnerable to further complications related to the liver, such as: hepatocellular carcinoma (liver cancer), liver failure, and liver cirrhosis.
Hepatitis C is most dangerous of among all the types of hepatitis as 80% of the hepatitis C infected patients get chronically infected. Around 150 million people are infected with hepatitis C worldwide and 350,000 people die every year. It has a cure rate of less than 80%, which drops below 60% in some regions of the world. The low cure rate is supplemented in most regions by a lack of an effective vaccine against hepatitis C. Recent estimates find that about 215,000 people in the UK are chronically infected with hepatitis C.
The global demand for Hepatitis C drug Market is expected to reach 27.63 billion USD in 2021 at a CAGR of 17% between 2016 and 2021, which was 11.81 billion USD in 2015. Key applications of hepatitis C drug market are hospitals, private labs, public health labs, blood banks and physician offices. Hepatitis C drug market can be driven by the elements like prevalence of the infection, new productive treatments, rising government subsidizing and relatively lesser time of treatment. Hepatitis C market can be influenced by treatment costs, lack of awareness and information about HCV disease.
In the United States, 20 percent to 30 percent of people living with HIV are coinfected with HCV. Hepatitis C is common among people living with HIV. This means that about 225,000 to 330,000 people in the United States are living with both viruses. The majority of people living with hepatitis C do not know they have it. The most common route of transmission in the UK is using non-sterile needles and other equipment for injecting drugs. 90 percent of people who got HIV from injecting drugs are also infected with HCV. This is because both viruses can be spread easily through blood and blood products.
HBV therapeutics market grow from $2.4 billion in 2014 to $3.0 billion in 2024 at a compound annual growth rate (CAGR) of 2.4%.
Siemens AG, MedMira Inc., Inovio Pharmaceuticals, Inc. and Abbott Laboratories are lead players involved in the development of hepatitis diagnostics.
Gilead Sciences launched couple of drugs Harvoni ((ledipasvir/sofosbuvir) and Sovaldi (sofosbuvir) in the market for Hepatitis C which captured maximum market share and has cure rate of more than 95%. In the coming years, ongoing research on hepatitis C drug development in pharmaceutical industry is expected to increase the market growth. Due to prevalence of the disease, interest for Hepatitis C medication is expanding in Africa, Middle East, Asia Pacific and Latin America.
Liver Associations
Drug Approvals and Launches:
In 2012, the European Commission approved the use of Viread for the treatment of chronic HBV infection. Viread is also approved for the treatment of HIV infection. Patent expiration for Viread in USA is 2018 and 2017 in EU.
In December 2013, FDA approved Sovaldi for the treatment of HCV as a component of a combination antiviral treatment regimen. In January 2014, European Commission approved Sovaldi for the treatment of HCV. Patent expiration for Sovaldi in USA is 2029 and 2028 in EU.
In October 2014, Gilead received FDA approval and in November 2014 Gilead received European Commission approval of Harvoni, the first once-daily single tablet regimen for the treatment of HCV genotype 1 infected patients. Patent expiration for Harvoni in USA and EU is 2030.
In December 2014,VIEKIRA PAK was approved by the FDA.
In July 2015, the FDA approved AbbVie's Technivie for use in combination with ribavirin for the treatment of adults with genotype 4 HCV infection in the United States.
In January 2016, the FDA approved Zepatier for the treatment of adult patients with chronic
HCV GT1 or GT4 infection, with or without ribavirin. Patent expiration for Intron A and Zepatier in USA is 2020 and 2031 respectively.
Novira Therapeutics is developing a lead core inhibitor candidate, NVR 3-778. NVR 3-778 is a potent inhibitor of HBV replication both in cell culture models and a humanized liver mouse model of CHB. It disrupts the HBV lifecycle by inducing the assembly of defective capsids. NVR 3-778 is currently under Phase 1 clinical trial in New Zealand.
Other Novira therapeutics drug such as “2nd Generation Core Inhibitor” and “cccDNA” inhibitor are under discovery stage of development.
FDA approved Drugs for HBV treatment:
FDA approved Drugs for HCV treatment:
Companies manufacturing Liver equipment’s
FDA approved drugs in 2016 for Hepatology
List of Manufacturing Companies:
Drugs in Clinical Development:
Tenofovir Alafenamide Fumarate (Gilead): TAF is a nucleotide reverse transcriptase inhibitor currently under Phase III stage of development for the treatment of Chronic HBV infection.
GS-9620 (Gilead): GS-9620 is a TLR-7 agonist indicated for Chronic HBV infection is under Phase II stage of development.
GS-4997 (Gilead): GS-4997 is an ASK-1 inhibitor indicated for NASH and alcoholic hepatitis is currently under Phase II stage of development.
GS-9674 (Gilead): GS-9674 is a FXR agonist indicated for NASH, Primary Sclerosing Cholangitis and Primary biliary cirrhosis is currently under Phase II stage of development.
3228836 (Glaxosmithkline): 3228836 is a HBV antisense oligonucleotide indicated for hepatitis B is currently under Phase I stage of clinical development.
3389404 (Glaxosmithkline): 3389404 is a HBV LICA antisense oligonucleotide indicated for hepatitis B is currently under Phase I stage of clinical development.
2878175 (Glaxosmithkline): 2878175 is a non-structural protein 5B (NS5B) polymerase inhibitor indicated for hepatitis C is currently under Phase I stage of clinical development.
ARO-HBV (Arrowhead): ARO-HBV is being developed for patients with chronic hepatitis B infection. It is currently under preclinical stage of development.
ARO-AAT (Arrowhead): ARO-AAT is being developed to treat the liver disease associated with alpha-1 antitrypsin deficiency. It is currently under preclinical stage of development.
Myrcludex-B (MYR GmbH): Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection completed Phase 2a clinical trial in chronic hepatitis B and a pilot trial in HDV infection is ongoing.
Market Analysis
GS-0976 (Gilead): GS-0976 is an ACC Inhibitor indicated for NASH is currently under Phase II stage of development.
UK Visa Information
London is the capital city of United Kingdom, stands on the River Thames and it is located in southeast of the island of Great Britain. London covers an area of 1579 square kilometres and according to 2017 statistics; Greater London’s population was estimated to be 9.26 million.
London is a prominent global city excelling in the fields of arts, education, commerce, fashion, entertainment, finance, media, healthcare, research and development, professional Services tourism, and transportation. As London is the world’s largest financial centre, serves as an attractive destination for international investors and businessmen.
7th International Conference on Hepatitis and Liver Diseases to have a meaningful discussion with scholars during May 02-03, 2019 in London, UK.
General required Documents for UK Visa
- Confirmation page of the application form DS-160 (You must show a printout of your DS-160 confirmation page when you arrive at the Embassy)
- One 5 x 5 cm (2” by 2”) colour photograph taken within the last six months
- A passport or other travel document (Your passport or travel document must be valid for at least six months beyond your stay in the United States and contain at least one blank page.)
- Evidence of your status in the United Kingdom (if you are not a U.K or EU passport holder)
- A copy of your return-ticket reservation. It is not recommended to purchase the ticket before obtaining the visa.
- A cover letter stating the aim to visit UK and itinerary.
- Flight Reservation with dates and flight numbers specifying entry and exit from UK
- Hotel Booking Reservation for the whole duration of the intended stay in UK
- Proof of civil status.
- Means of subsistence – Proof of sufficient financial means for the period of stay in UK.
Having query regarding Visa ?
we will help you in your every step regarding the approval of UK Visa
Just Email us to know more details:
Media Partners/Collaborator
A huge thanks to all our amazing partners. We couldn’t have a conference without you!
Sponsors/Exhibitors
A huge thanks to all our amazing partners. We couldn’t have a conference without you!
